moderate - As a pre-revenue technology company, near-term sensitivity to GDP is limited. However, future demand for enriched isotopes correlates with semiconductor capital spending (cyclical), medical diagnostic volumes (relatively stable), and research budgets (government-dependent). The company's ability to raise capital is highly sensitive to risk appetite in equity markets, which correlates with economic conditions. Once operational, revenue will be more stable due to long-term supply contracts typical in specialty chemical markets.

High sensitivity through multiple channels. Rising rates increase: (1) discount rates applied to distant future cash flows, compressing valuation multiples for pre-revenue growth companies; (2) cost of capital for facility construction if debt financing is used; (3) opportunity cost for investors comparing speculative equities to risk-free rates. The company's current 6.14x current ratio suggests adequate liquidity, but future capital needs may require equity raises at dilutive valuations if rates remain elevated. Conversely, falling rates would improve valuation multiples and reduce financing costs for the capital-intensive buildout phase.

growth/speculative - The stock attracts high-risk-tolerance investors seeking asymmetric returns from successful technology commercialization. With no meaningful revenue, negative margins, and binary outcomes tied to facility commissioning, this is a venture-stage equity investment rather than traditional value or income play. The investor base likely includes retail momentum traders, thematic investors focused on semiconductor supply chain or quantum computing, and specialized deep-tech venture funds. Institutional ownership is likely limited given pre-revenue status and small market cap.